Dyax Corp


  • *U.S launch could be in 2017, peak U.S. sales of $1.2 bln. May 27- BioCryst Pharmaceuticals Inc's oral drug to prevent a hereditary disorder characterized by abnormal swelling was effective in reducing attacks, sending the drugmaker's shares up as much as 22 percent.

  • Stocks to Watch: DELL, QSFT, GSK & More Thursday, 14 Jun 2012 | 6:34 PM ET

    Check out which companies are making headlines after the bell Thursday:

  • It's Time for the Lightning Round! Monday, 16 Apr 2007 | 6:41 PM ET

    Starbucks, Tribune, Nastech! Buy or sell? Cramer's got you covered.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Dyax said its product candidate for hereditary angioedema, a genetic disease, met its main goal in a late-stage trial, sending the biopharmaceutical company's shares up more than 40% in after-hours trading.